FDA approves Namzaric to treat Alzheimer's disease
from Pharmacy Times
The FDA has approved Namzaric, a fixed-dose combination of memantine hydrochloride extended-release, an N-methyl D-aspartate receptor antagonist, and donepezil hydrochloride, an acetylcholinesterase inhibitor.
7701 Las Colinas Blvd., Ste. 800, Irving, TX 75063